REGN — Regeneron Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $66.35bn
- $60.31bn
- $14.34bn
Regeneron falls after eye-drug sales miss expectations
Regeneron beats quarterly estimates on strong Dupixent demand (updated)
Regeneron beats quarterly results estimates on strong Dupixent demand
Regeneron Q1 revenue beats estimates on EYLEA HD sales
U.S. STOCKS ON THE MOVE- Lululemon, United Rentals, cannabis stocks
FDA approves Regeneron's gene therapy for inherited deafness (updated)
FDA approves Regeneron's gene therapy for inherited deafness
White House to announce drug pricing deal with Regeneron, source says (updated)
White House to announce drug pricing deal with Regeneron, source says
U.S. STOCKS ON THE MOVE- American Airlines, Pot stocks, Paramount Skydance
U.S. STOCKS ON THE MOVE-IBM, American Airlines, Texas Instruments
U.S. STOCKS ON THE MOVE-Honeywell, Netflix, CSX
TD Cowen raises Regeneron's PT on huge potential for myasthenia gravis drug
Brief: Regeneron Pharmaceuticals Announces Positive Phase 3 NIMBLE Trial Results For Cemdisiran In gMG
Telix rises as it enters into cancer deal with Regeneron
Australia's Telix Pharmaceuticals rises on $40 mln Regeneron deal; Citi sees 'broader' scope
Brief: Telix And Regeneron Announce Radiopharma Collaboration
Brief: Trinetx Collaborates With Regeneron To Access De-Identified Electronic Health Records Of 300 Million Patients To Drive Research And Product Development In Life Sciences And Digital Health Solutions
Brief: Regeneron Collaborates With Trinetx To Access De-Identified Electronic Health Records Of 300 Million Patients To Drive Research And Product Development In Life Sciences And Digital Health Solutions